Sanara Medtech Inc

SMTI

Monteverde & Associates investigates four mergers for potential shareholder claims

Monteverde & Associates PC is investigating four proposed acquisitions for potential breaches of fiduciary duty and other violations of law. The firm is examining the sale of Forte Biosciences to argenx BV at $77.00 per share in cash, Luxfer Holdings to affiliates of Wynnchurch Capital at $17.37 per share in cash, Sanara MedTech to MiMedx Group for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and MarketAxess Holdings to Intercontinental Exchange at $167.00 per share in cash. Shareholders are encouraged to contact the firm before the applicable tender offer deadlines, including August 26, 2026 for Forte Biosciences.

FBRX ▲ICE ▲LXFR ▲MDXG ▲MKTX ▲SMTI

GlobeNewswire·20dRead more ▾

SMTI2

Halper Sadeh LLC Investigates Fairness of Deals for FBRX, LXFR, SMTI, MKTX

Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed sales of Forte Biosciences, Luxfer Holdings, Sanara MedTech, and MarketAxess Holdings are fair to shareholders. The firm is examining Forte Biosciences' sale to argenx for $77.00 per share in cash, Luxfer Holdings' sale to affiliates of Wynnchurch Capital for $17.37 per ordinary share in cash, Sanara MedTech's sale to MiMedx Group for $33.00 in cash and 0.4735 shares of MiMedx common stock per Sanara share, and MarketAxess Holdings' sale to Intercontinental Exchange for $167.00 per share in cash. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, and encourages affected investors to contact the firm to discuss their legal rights and options at no cost.

FBRX LXFR MKTX SMTI

GlobeNewswire·21dRead more ▾

SMTI

Brodsky & Smith investigates boards of MarketAxess, CBIZ, Sanara MedTech, and TriCo Bancshares over merger deals

Brodsky & Smith is investigating the boards of MarketAxess Holdings, CBIZ, Sanara MedTech, and TriCo Bancshares for potential breaches of fiduciary duty in connection with their respective merger agreements. The investigations concern whether the boards failed to conduct a fair process and whether the proposed transactions pay fair value to shareholders. MarketAxess is being acquired by Intercontinental Exchange for $167 per share in cash, representing an equity value of approximately $6.0 billion. CBIZ is being acquired by Grant Thornton Advisors for $55.00 per share in an all-cash deal with an enterprise value of $5 billion. Sanara MedTech is being acquired by MiMedx Group in a cash and stock transaction valued at $35 per share with a total enterprise value of approximately $350 million. TriCo Bancshares is being acquired by First Hawaiian in an all-stock deal where TriCo shareholders will receive 2.095 First Hawaiian shares for each TriCo share, representing $63.12 per share based on First Hawaiian's closing price on July 10, 2026.

CBZ MKTX SMTI TCBK

GlobeNewswire·22dRead more ▾

Biotech & Genomic Medicine▲

SciSparc, Avantor, NeoGenomics Lead Biotech Gains on Milestones and Upgraded Outlooks

Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.

ALVO ▲AVTR ▲LBRX ▲MDXG ▲NEO ▲SMTI ▲+1

Biotech & Genomic Medicine ▲

RTTNews·28dRead more ▾

SMTI▲

MIMEDX Reports Second Quarter Net Sales of $64 Million and Plans to Acquire Sanara MedTech

MIMEDX announced second quarter 2026 net sales of $64 million, a 35% decline from the prior year, and separately unveiled a definitive agreement to acquire Sanara MedTech in a cash-and-stock deal valued at approximately $350 million. Surgical product sales grew 15% year-over-year, led by AMNIOFIX and AMNIOEFFECT, while Wound sales fell 61% due to Medicare reimbursement changes that took effect on January 1. The company reported a net loss of $15 million for the quarter, compared to net income of $10 million a year earlier, and held $136 million in cash and equivalents as of June 30. MIMEDX reiterated its full-year 2026 net sales guidance of $260 to $290 million and expects Adjusted EBITDA to approach breakeven. Under the Sanara acquisition terms, Sanara shareholders will receive $33.00 in cash and 0.4735 shares of MIMEDX common stock per share, representing a 46% premium to Sanara’s 30-day volume-weighted average price, with the transaction expected to close by year-end subject to shareholder and regulatory approvals.

MDXG ▼SMTI ▲

GlobeNewswire·28dRead more ▾